Brand Name | Status | Last Update |
---|---|---|
atripla | New Drug Application | 2024-07-09 |
atripla access | Export only | 2021-04-12 |
biktarvy | New Drug Application | 2025-01-15 |
cimduo | New Drug Application | 2021-02-15 |
complera | New Drug Application | 2024-09-24 |
complera access | Export only | 2024-09-23 |
delstrigo | New Drug Application | 2025-01-28 |
descovy | New Drug Application | 2025-02-07 |
efavirenz, emtricitabine and tenofovir disoproxil fumarate | ANDA | 2024-06-27 |
efavirenz, lamivudine and tenofovir disoproxil fumarate | ANDA | 2024-05-07 |
Expiration | Code | ||
---|---|---|---|
DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL FUMARATE, DELSTRIGO, MSD MERCK CO | |||
2025-01-27 | NPP |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate, Delstrigo, Msd Merck Co | |||
10603282 | 2036-11-29 | DP | |
10842751 | 2036-11-29 | DP | |
8486975 | 2031-10-07 | DS, DP | U-2395, U-2629, U-3307 |
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate, Complera, Gilead Sciences Inc | |||
10857102 | 2033-01-14 | DP | |
8841310 | 2025-12-09 | DP | U-257 |
7125879 | 2025-04-21 | DS, DP | U-257 |
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Disoproxil Fumarate, Stribild, Gilead Sciences Inc | |||
10039718 | 2032-10-06 | DP | |
8633219 | 2030-04-30 | DP | U-257 |
8148374 | 2029-09-03 | DS, DP | U-1279 |
9891239 | 2029-09-03 | DP | U-257 |
7635704 | 2026-10-26 | DS, DP | U-257 |
8981103 | 2026-10-26 | DS, DP | |
7176220 | 2026-08-27 | DS, DP | U-257 |
8592397 | 2024-01-13 | DP | U-248, U-257, U-541, U-750, U-1170 |
8716264 | 2024-01-13 | DP | U-257 |
9457036 | 2024-01-13 | DP | U-257 |
9744181 | 2024-01-13 | DP | U-257 |
Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate, Atripla, Gilead Sciences | |||
8598185 | 2029-04-28 | DP | |
9018192 | 2026-06-13 | U-750, U-1170 | |
9545414 | 2026-06-13 | DP | U-750, U-1170 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis b | D006509 | — | — | — | — | — | 1 | — | 1 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | — | — | — | 1 | — | 1 |
Hepatitis | D006505 | — | K75.9 | — | — | — | 1 | — | 1 |
Chronic hepatitis | D006521 | — | K73.9 | — | — | — | 1 | — | 1 |
Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | — | 1 |
Drug common name | Tenofovir |
INN | tenofovir |
Description | Tenofovir disoproxil is an organic phosphonate that is the disoproxil ester of tenofovir. A prodrug for tenofovir, an HIV-1 reverse transcriptase inhibitor, tenofovir disoproxil is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. It has a role as a prodrug, a HIV-1 reverse transcriptase inhibitor and an antiviral drug. It is functionally related to a tenofovir (anhydrous). |
Classification | Small molecule |
Drug class | antivirals |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O |
PDB | — |
CAS-ID | 147127-20-6 |
RxCUI | — |
ChEMBL ID | CHEMBL483 |
ChEBI ID | 63625 |
PubChem CID | 5481350 |
DrugBank | DB00300 |
UNII ID | W4HFE001U5 (ChemIDplus, GSRS) |